financetom
Business
financetom
/
Business
/
Lowe's cuts annual forecasts on weak home improvement demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lowe's cuts annual forecasts on weak home improvement demand
Aug 20, 2024 3:40 AM

(Reuters) -Lowe's cut its annual profit and sales forecasts on Tuesday, joining bigger rival Home Depot in issuing bleak projections as economic concerns keep consumers from splurging on pricy home improvements.

Higher borrowing and mortgage rates have led to subdued demand for new homes - a factor that weighed on sales at Lowe's and Home Depot.

Placer.ai data showed that fewer new home sales in May and June pressured store traffic for the home improvement companies.

Home Depot also forecast a decline in annual profit and a bigger drop in annual comparable sales last week, signaling that revival of consumer demand would take a while.

Unusually warm weather also dented sales for both home improvement companies as consumers put off renovation projects for their lawns and homes this spring season.

Lowe's second-quarter comparable sales fell 5.1%, more than analysts' expectation of a 4.11% drop, per LSEG data.

The company now expects full-year adjusted earnings per share of about $11.70 to $11.90, down from about $12.00 to $12.30.

It sees a 3.5% to 4% drop in comparable sales for 2024, compared with its earlier forecast of a 2% to 3% drop.

Shares of the company were down marginally in premarket trading.

(Reporting by Juveria Tabassum; Editing by Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
BRIEF-Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
Jul 11, 2024
July 11 (Reuters) - Johnson & Johnson: * JOHNSON & JOHNSON STRENGTHENS PIPELINE TO LEAD IN ATOPIC DERMATITIS WITH THE COMPLETION OF THE ACQUISITION OF YELLOW JERSEY THERAPEUTICS, GAINING OWNERSHIP OF NM26 Source text for Eikon: Further company coverage: ...
Leidos awarded $476 million NASA cargo mission support contract
Leidos awarded $476 million NASA cargo mission support contract
Jul 11, 2024
July 11 (Reuters) - Leidos ( LDOS ) said on Thursday it was awarded a contract to continue providing cargo mission engineering and integration services for NASA's International Space Station Program and Artemis campaign. The contract is valued at $476 million, with a base performance period of two years. ...
PepsiCo quarterly revenue misses estimates as demand slows for snacks, sodas
PepsiCo quarterly revenue misses estimates as demand slows for snacks, sodas
Jul 11, 2024
July 11 (Reuters) - PepsiCo ( PEP ) missed expectations for second-quarter revenue on Thursday as a series of price hikes and competition from private-label brands slowed sales of its snacks and soda mainly in the United States, its largest market. Analysts have said that product prices, which are starting to normalize almost after two years of multiple hikes, are...
Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor
Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor
Jul 11, 2024
08:16 AM EDT, 07/11/2024 (MT Newswires) -- Akebia Therapeutics ( AKBA ) said Thursday that it has regained full rights to commercialize Vafseo tablets in the US after agreeing to terminate a license agreement with CSL Vifor. Akebia said it is now allowed to deal directly with all dialysis organizations effective immediately. Akebia said CSL Vifor is entitled to quarterly...
Copyright 2023-2026 - www.financetom.com All Rights Reserved